Nancy Pryer

9.2k citations

35 papers · 6.2k indexed · 6 hit papers · h-index 22

Impact in

Cell Biology top 0.5%
- Microtubule and mitosis dynamics
- Cellular transport and secretion
- Cellular Mechanics and Interactions
Oncology top 1%
- Cancer-related Molecular Pathways
- Cancer Immunotherapy and Biomarkers

Papers in

Cell Biology 11
- Microtubule and mitosis dynamics 8
- Cellular Mechanics and Interactions 3
Oncology 16
- HER2/EGFR in Cancer Research 5
- Cancer Cells and Metastasis 3
- Cancer-related Molecular Pathways 3

Co-authors: Edward D. Salmon R. A. Walker Julie M. Cherrington Tinya J. Abrams Randy Schekman Lesley Murray Leslie B. Lee Lynne Cassimeris
Journals: Cancer Research (6 papers)The Journal of Cell Biology (4 papers)Blood (4 papers)Molecular Cancer Therapeutics (3 papers)Cancer Cell (1 paper)
Partner nations: United States Switzerland United Kingdom

In The Last Decade

Nancy Pryer

33 papers receiving 6.1k citations

Hit Papers

6 papers align trajectories log scale

Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells 2014 · 758 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2014 Cancer Cell
2013 Nature
2004 Molecular Cancer Therapeutics
2003 PubMed
1992 Annual Review of Biochemistry
1988 The Journal of Cell Biology

Peers

Countries citing papers authored by Nancy Pryer

Since Specialization

Citations

This map shows the geographic impact of Nancy Pryer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nancy Pryer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nancy Pryer more than expected).

Fields of papers citing papers by Nancy Pryer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nancy Pryer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nancy Pryer. The network helps show where Nancy Pryer may publish in the future.

Co-authors

The 25 scholars most cited alongside Nancy Pryer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Nancy Pryer Line = papers co-authored together Nancy Pryer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Real-time observations of microtubule dynamic instability in living cells UNC Libraries ·Liqiong Yu, Nancy Pryer, 慶岡久	2021	0
2	Impact of Pre-Existing Immunogenicity to AAV on Vector Transduction By Bmn 270, an AAV5-Based Gene Therapy Treatment for Hemophilia A Blood ·Brian Long, Ugras Daban, Jennifer Holcomb, J.C. Chipman, 英二神藤, PJDO Lima, B. V. Carino, Henry Ringling North, Charles O’Neill, Nancy Pryer, Carlos Fonck, Stephen J. Zoog, Christian Vettermann	2017	2
3	Interim Analysis of Immunogenicity to the Vector Capsid and Transgene-Expressed Human FVIII in a Phase-1/2 Clinical Study of Bmn 270, an AAV5-Mediated Gene Therapy for Hemophilia a Blood ·Brian Long, Benjamin Kim, Wing Yen Wong, Kehu Yang, Christian Vettermann, Nancy Pryer, Romain Hardet, Klaudia Kuranda, P. Véron, Federico Mingozzi, Glenn F. Pierce, Becky Schweighardt	2017	1
4	Vemurafenib Cooperates with HPV to Promote Initiation of Cutaneous Tumors Cancer Research ·Matthew Holderfield, Edward Lorenzana, Ben Weisburd, S. Nonogaki, Lise Boussemart, Ludovic Lacroix, Gorana Tomasic, Michel Fãvre, Stéphan Vagner, Caroline Robert, Majid Ghoddusi, 由朗坂崎, Nancy Pryer, Frank McCormick, Darrin D. Stuart	2014	20
5	Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells Cancer Cell ·Brian Ruffell, Mariana D'Angelo, Vivien W. Chan, Cláudia da Luz Carvelli, Christine M. Ho, Nancy Pryer, Dylan Daniel, E. Shelley Hwang, Hope S. Rugo, Lisa M. Coussens Hit paper breakdown →	2014	758
6	CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8⁺T cells OncoImmunology ·Debbie Strachan, Brian Ruffell, Yoko Oei, Mina J. Bissell, Lisa M. Coussens, Nancy Pryer, Dylan Daniel	2013	314
7	Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance Nature ·Meghna Das Thakur, Fernando Salangsang, Allison Landman, William R. Sellers, Nancy Pryer, Mitchell P. Levesque, Reinhard Dummer, Martin McMahon, Darrin D. Stuart Hit paper breakdown →	2013	539
8	Mouse tumour models to guide drug development and identify resistance mechanisms The Journal of Pathology ·Meghna Das Thakur, Nancy Pryer, Mallika Singh	2013	18
9	The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo Molecular Cancer Therapeutics ·Daniel L. Menezes, Pietro Taverna, Michael Rugaard Jensen, Tinya J. Abrams, Darrin D. Stuart, Guoying Karen Yu, David M. Duhl, Timothy Machajewski, William R. Sellers, Nancy Pryer, Zhenhai Gao	2012	57
10	Abstract #DDT02-2: MCS110: a monoclonal antibody with potent neutralizing activity against macrophage colony-stimulating factor for the treatment of tumor-induced osteolysis Cancer Research ·Nancy Pryer, Victoria Sung, Ursula Jeffry, Jing Peng, Yoko Oei, Ying Cao, Arnold H. Horwitz, Kathleen Meyer, Janet E. Price, Cheng Liu, Michael Kavanaugh, Judith A. Abraham	2009	1
11	CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3–Expressing Orthotopic Multiple Myeloma Model in Mice Clinical Cancer Research ·Xiaohua Xin, Tinya J. Abrams, Paul W. Hollenbach, Katherine G. Rendahl, Yan Tang, Yoko Oei, Millicent Embry, Marco De Ferrari, Evelyn N. Garrett, Nancy Pryer, Suzanne Trudel, Bahija Jallal, Dirk B. Mendel, Carla Heise	2006	53
12	CHIR-258 Efficacy in a Newly Developed Preclinical Bone Marrow Model of t(4;14) Multiple Myeloma. Blood ·Xiaohua Xin, Yan Tang, Yoko Oei, Helen Ye, Daniel L. Menezes, Katherine G. Rendahl, Paul W. Hollenbach, Nancy Pryer, Suzanne Trudel, Dirk B. Mendel, Bahija Jallal, Carla Heise	2005	1
13	Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts Molecular Cancer Therapeutics ·David W. Fry, Patricia J. Harvey, Paul R. Keller, William L. Elliott, R. Maoli, Erin Trachet, Mudher Albassam, Xianxian Zheng, Wilbur R. Leopold, Nancy Pryer, Peter L. Toogood Hit paper breakdown →	2004	982
14	Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. PubMed ·Nancy Pryer, Leslie B. Lee, Bertha Nathalia Kramer, Xiaoming Yu, Juthamas Sukbuntherng, Julie M. Cherrington, Cheryl A. London	2003	92
15	Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. PubMed ·Tinya J. Abrams, Lesley Murray, Enrico Pesenti, Kazunari Ooyama, Tina Colombo, Leslie B. Lee, Julie M. Cherrington, Nancy Pryer	2003	215
16	SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model Clinical & Experimental Metastasis ·Lesley Murray, Tinya J. Abrams, R. Manweiler, Claudiu Sorin Voinia, Lisa Olson, BINAEBI EDUBAMO DAVIDSON, Paul Keast, Jacqueline Brassard, A O’Farrell, Julie M. Cherrington, Nancy Pryer	2003	254
17	Characterizing the Interactions between the Two Subunits of the p101/p110γ Phosphoinositide 3-Kinase and Their Role in the Activation of This Enzyme by Gβγ Subunits Journal of Biological Chemistry ·Sonja Krugmann, Phillip T. Hawkins, Nancy Pryer, Sylvia Braselmann	1999	74
18	Effects of electric fields on fibroblast contractility and cytoskeleton Journal of Experimental Zoology ·Albert K. Harris, Nancy Pryer, David Paydarfar	1990	25
19	Real-time observations of microtubule dynamic instability in living cells. The Journal of Cell Biology ·Lynne Cassimeris, Nancy Pryer, Edward D. Salmon	1988	308
20	Polarized microtubule gliding and particle saltations produced by soluble factors from sea urchin eggs and embryos Cell Motility and the Cytoskeleton ·Nancy Pryer, Patricia Wadsworth, Edward D. Salmon	1986	38

About Nancy Pryer

Nancy Pryer is a scholar working on Cell Biology, Oncology, Molecular Biology, Hematology and Physiology, having authored 35 papers that have together received 6.2k indexed citations. Recurring topics across this work include Microtubule and mitosis dynamics (8 papers), HER2/EGFR in Cancer Research (5 papers), Protist diversity and phylogeny (4 papers), Melanoma and MAPK Pathways (4 papers), Radiopharmaceutical Chemistry and Applications (3 papers), Cellular Mechanics and Interactions (3 papers), Cancer Cells and Metastasis (3 papers) and Cancer-related Molecular Pathways (3 papers). The work is most often cited by research in Cell Biology (2.1k citations), Oncology (2.4k citations), Immunology (1.1k citations), Molecular Biology (3.4k citations) and Pulmonary and Respiratory Medicine (1.4k citations). Nancy Pryer has collaborated with scholars based in United States, Switzerland and United Kingdom. Frequent co-authors include Edward D. Salmon, R. A. Walker, Julie M. Cherrington, Tinya J. Abrams, Randy Schekman, Lesley Murray, Leslie B. Lee, Lynne Cassimeris, Linda J. Wuestehube and Brian Ruffell. Their work appears in journals such as Cancer Research, The Journal of Cell Biology, Blood, Molecular Cancer Therapeutics and Cancer Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact